Jazz Pharmaceuticals
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell JAZZ and other ETFs, options, and stocks.About JAZZ
Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio.
JAZZ Key Statistics
Stock Snapshot
The current Jazz Pharmaceuticals(JAZZ) stock price is $180.56, with a market capitalization of 10.97B. The stock trades at a price-to-earnings (P/E) ratio of -29.15.
As of 2025-11-24, Jazz Pharmaceuticals(JAZZ) stock has fluctuated between $172.19 and $182.27. The current price stands at $180.56, placing the stock +4.9% above today's low and -0.9% off the high.
The Jazz Pharmaceuticals(JAZZ)'s current trading volume is 1.21M, compared to an average daily volume of 2.11M.
During the past year, Jazz Pharmaceuticals(JAZZ) stock moved between $95.49 at its lowest and $182.99 at its peak.
During the past year, Jazz Pharmaceuticals(JAZZ) stock moved between $95.49 at its lowest and $182.99 at its peak.
JAZZ News
UBS analyst Ashwani Verma downgraded Jazz Pharmaceuticals (JAZZ) to Neutral from Buy with a price target of $188, up from $163. Following the strong Phase 3 GEA...
Jazz Pharmaceuticals (JAZZ) released results from its Phase 3 HERIZON-GEA-01 trial, showing Ziihera combinations led to marked improvements in survival measures...
New insider activity at Jazz Pharmaceuticals ( (JAZZ) ) has taken place on November 20, 2025. TipRanks Black Friday Sale Claim 60% off TipRanks Premium for the...
Analyst ratings
84%
of 19 ratingsMore JAZZ News
On November 17, 2025, Jazz Pharmaceuticals announced positive top-line results from the Phase 3 HERIZON-GEA-01 trial, showing that Ziihera combined with chemoth...
Despite an already strong run, Jazz Pharmaceuticals plc ( ) shares have been powering on, with a gain of 25% in the last thirty days. Looking back a bit further...
Jazz Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason Gerberry from Bank of America Securities re...